Fall 2013

Drug research and development continues to focus on regimens that select therapy according to the pathologic and molecular characteristics of the tumor.

Headlines from the June meeting of the American Society of Clinical Oncology (ASCO) in Chicago announced to the general public what oncologists and hematologists have known for more than two years: sporadic shortages of cancer drugs are forcing suboptimal treatment plans for patients, and government efforts have not filled the void.